IMMUNOTHERAPY

The JULIET trial reveals long-term efficacy and safety of CAR-T therapy tisagenlecleucel in relapsed/refractory large B-cell lymphoma patients.

A novel combination therapy shows promising results in extending progression-free survival for patients with advanced pancreatic cancer, highlighting potential biomarkers for immunotherapy.

OBI-902 receives FDA orphan drug designation for cholangiocarcinoma, promising new hope in treating this rare and aggressive cancer.

DPTX3186 gains FDA fast track status, promising a novel treatment for gastric cancer with potential for significant patient impact.

Zanidatamab plus chemotherapy shows significant survival benefits for HER2-positive gastroesophageal adenocarcinoma, potentially transforming first-line treatment options.

The FDA grants fast track designation to 4A10, a promising monoclonal antibody for treating relapsed acute lymphoblastic leukemia in children.

FOG-001 receives FDA fast track designation, promising new hope for desmoid tumor patients with its innovative approach to treatment.

MB-105 receives FDA RMAT designation, advancing treatment options for relapsed T-cell lymphoma and highlighting its promising clinical potential.

FDA fast-tracks alnodesertib and irinotecan for ATM-negative metastatic colorectal cancer, showing promising efficacy and safety in early trials.

The FDA clears the way for a pivotal phase 3 trial of lacutamab, promising new hope for patients with cutaneous T-cell lymphomas.

Tinostamustine receives FDA orphan drug designation, promising new hope for glioblastoma treatment with innovative dual-action mechanism.

In an interview with Targeted Oncology, Frederick L. Locke, MD, discussed how the elimination of the REMS program for CAR T-cell therapy came about and what effects he hopes this will have on patient access.

A new treatment combination shows significant promise for patients with resistant gastrointestinal stromal tumors, improving survival rates and tolerability.

New findings reveal promising antitumor responses in HER2-positive esophagogastric adenocarcinoma with a novel chemoimmunotherapy approach.

A phase 1b trial reveals the safety and potential efficacy of combining PolyPEPI1018 vaccine with TAS-102 in treating advanced colorectal cancer.

Glofitamab and polatuzumab vedotin show promising efficacy and safety in treating relapsed/refractory large B-cell lymphoma, with durable responses reported.

Innovations in cancer immunotherapy highlight the urgent need for effective management of immune-related toxicities, emphasizing precision medicine and interdisciplinary collaboration.

Izalontamab shows promise as a safe treatment for advanced epithelial tumors, demonstrating early antitumor activity in a recent clinical trial.

The EDGE-Gastric trial reveals promising results for domvanalimab and zimberelimab in treating advanced gastric cancer, showcasing durable efficacy and manageable safety.

Vorasidenib shows significant long-term benefits for IDH-mutant glioma patients, enhancing survival and delaying treatment needs post-surgery.

Community-based CAR T-cell therapy expands access to innovative cancer treatments, improving patient outcomes and reducing hospital stays for patients with blood cancers.

Whole-genome sequencing uncovers critical genomic insights in salivary gland cancer, paving the way for targeted therapies and improved patient outcomes.

A novel combination therapy shows promising results for advanced esophageal squamous cell carcinoma, achieving high response rates and manageable safety.

VS-7375 shows promising safety and antitumor activity in advanced solid tumors with KRAS G12D mutation, paving the way for further clinical evaluation.